Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received approval from the United States Food and Drug Administration (USFDA).
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 50 mg of Astellas Pharma Global Development. Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of $ 1,600 million in the US (IQVIA MAT July 2024).